Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary

What happened

Pulmonx reported third-quarter 2026 revenue of $22.84 million, up 6.2% from a year earlier. Net loss was $8.39 million, and diluted loss per share was $0.19 versus $0.34 before.

Confirmed

Global impact / market context

A smaller loss on slightly higher sales means Pulmonx is losing less money per dollar of revenue, which reduces the need for outside funding. Higher Zephyr Valve procedure volumes drive that revenue, so procedure growth is the key lever for future results.

Analyst inference

Nine-month revenue fell 2.5% to $66.2 million because U.S. procedure volumes were lower and China shipments paused. China registration was renewed in June 2026, and shipments should resume by early 2027, so the yearly trend trails the quarterly rebound.

Analyst inference

What to watch

1. Pulmonx expects distributor shipments to China to resume by early 2027 after its China registration was renewed in June 2026, which matters because the nine-month revenue decline included the shipment pause. Confirmed
2. Watch whether U.S. Zephyr Valve procedure volumes keep rising, since the company credits them for quarterly growth and lower U.S. volumes weighed on nine-month revenue. Proposed
3. Track the AeriSeal CONVERT II trial, which is underway to support a potential U.S. marketing application; a positive result could add a second product and new revenue, while a setback would leave Pulmonx reliant on Zephyr. Analyst inference

Evidence

• Original source link unavailable